Hospital Privado de la Comunidad

Hospital Privado de la Comunidad
Córdoba 4545, Mar del Plata, Buenos Aires
Select an option

Our team

Medical staff
Laura Chueca
Marcos Flores
Pamela Herner
Lucia Cardonnet
Pablo Capellino
Ignacio Alfredo Casarini
Álvaro Facta

Open studies

Lung cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations - TROPION-Lung08 - AstraZenecaSee more
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) - TROPION-Lung07 - AstraZenecaSee more
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib - COCOON - Janssen Research & Development, LLCSee more
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% - RELATIVITY1093 - Bristol-Myers SquibbSee more
Bladder Cancer
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) - SunRISe-5 - Janssen Research & Development, LLCSee more
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer - MoonRISe-1 - Janssen Research & Development, LLCSee more
Colorectal cancer
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer - AZUR-2 - GlaxoSmithKlineSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy